By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) said it plans to conduct a clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation for severe obstructive sleep apnea treatment. This follows positive preliminary data from a study that...

By Daniella Parra Psychotropic industry innovator Lucy Scientific Discovery Inc. (Nasdaq: LSDI), has appointed Richard Nanula, former CFO at Amgen Inc. (Nasdaq: AMGN) and The Walt Disney Co. (NYSE: DIS), as its new CEO. With a career spanning senior executive...

By Daniella Parra Marti Technologies Inc. announced that its Class A Ordinary Shares and warrants have commenced trading on the NYSE American Stock Exchange under the symbols “MRT” and “MRTW,” respectively. One of the first Turkish companies to list in...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) announced the appointment of Brant Binder, a seasoned leader and entrepreneur with more than 25 years of strategic expertise building and growing biotechnology companies and Richard Wagner, Ph.D., a biotechnology entrepreneur with more than...

By Daniella Parra On Holding AG (NYSE: ONON) said it is opening a new store in Brooklyn’s Williamsburg neighborhood to meet growing consumer demand. The store features interactive spaces and will host weekly run clubs with designs that incorporate elements...

By Daniella Parra A recent survey by ProSomnus, Inc. (NASDAQ: OSA) and Proedge revealed that 71% of snorers have never sought medical advice. Obstructives Sleep Apnea (OSA) is a recurring airway collapse during sleep, linked to serious comorbidities. Over one...

By Daniella Parra Prenetics Global Limited (NASDAQ: PRE) and Prof. Dennis Lo, the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong have formed a joint venture named Insighta, aiming to revolutionize multi-cancer early detection screening....

  Nationally relevant news stories frequently carry financial significance as well. Recently, Mark Hauser’s Hauser Private Equity returned significant capital to its investors from two headlining investments, the CAVA IPO (via fund partner Revolution) and the Staple Street Group’s settlement...

By Daniella Parra Swiss life sciences company Lunaphore Technologies SA has agreed to be acquired by Bio-Techne Corporation, (NASDAQ:TECH) a global provider of tools and reagents for research and diagnostics. Lunaphore’s advanced microfluidic technology enables the analysis of biomarkers in...

By Daniella Parra Vaxxinity (Nasdaq: VAXX) has revealed encouraging findings from the Phase 1b clinical trial of UB-312, their vaccine candidate targeting alpha-synuclein for the treatment and prevention of Parkinson’s disease (PD) and other synucleinopathies. The study demonstrated that UB-312...